Why this list matters for allergy care accessed from home

Telehealth has become a durable part of allergy care, with very high patient satisfaction and a growing role in closing access gaps created by specialist shortages. For allergy and immunology, synchronous and asynchronous telemedicine models are now well-established and can safely support longitudinal management, including immunotherapy programs, when paired with clear protocols for monitoring and follow‑up.

What to look for (objective criteria)

• Modality of care: immunotherapy (sublingual drops or FDA‑approved tablets), prescription medication management (custom nasal sprays, antihistamines), or hybrid models.

• Physician involvement and follow‑up: board‑certified clinicians, cadence of check‑ins, 24/7 access.

• First‑dose rules: FDA‑approved SLIT tablets (e.g., dust mite, grass, ragweed) require the first dose under medical supervision with 30‑minute observation; custom drops typically do not.

• Testing options: at‑home CLIA lab panels vs. use of existing results.

• Pricing transparency: lowest publicly advertised monthly cost (treatment only unless noted), billing cadence, and what’s included.

• Insurance and payment: whether visits and/or medication are billed to insurance; FSA/HSA eligibility; any money‑back guarantees.

Last updated: November 3, 2025 (United States).

Methods (how we built this)

• Inclusion: U.S. telehealth or hybrid services that publicly advertise personalized allergy treatment plans and pricing, and that operate nationally or in multiple states.

• Data collection: Review of official product/support pages and prescribing information for first‑dose requirements (for SLIT tablets). All pricing and policies were verified on November 3, 2025.

• Exclusion: Local-only brick‑and‑mortar clinics without a telehealth pathway, marketplaces that only sell OTC drugs without clinical oversight, and services without transparent pricing pages.

• Note: Insurance coverage for custom sublingual drops is uncommon in the U.S.; some platforms bill clinical visits to insurance while drops are self‑pay.

Quick compare (at‑a‑glance)

Provider snapshots (neutral summaries)

1) Wyndly

• What it is: Physician‑led telehealth program offering personalized sublingual immunotherapy via custom drops or FDA‑approved tablets, with at‑home CLIA testing and nationwide shipping. Advertises therapy from $99/month and a $49 initial consult, with FSA/HSA eligibility and a money‑back guarantee if not satisfied. 24/7 doctor access.

• First‑dose rule: If tablets (e.g., dust‑mite or grass) are selected, the initial dose must be observed in a healthcare setting with 30‑minute monitoring per product labeling; drops do not require supervised first dose.

2) Curex

• What it is: Telehealth service for SLIT drops with optional testing; lists a Smart Saver plan “from $59/month” for drops, and bills clinical consultations to insurance (average annual patient responsibility may apply). HSA/FSA accepted. Curex notes routine prescription of epinephrine autoinjectors as a precaution for patients on drops.

• First‑dose rule: Custom drops are taken at home; if an FDA‑approved tablet is used, the first dose must be supervised per labeling.

3) Nectar Allergy

• What it is: Telehealth program focused on personalized SLIT allergy drops. Pricing: Allergy drops $99/month billed quarterly; many customers begin with an at‑home test (commonly cited at $199). Nectar indicates drops are not insurance‑covered but are FSA/HSA‑eligible.

• First‑dose rule: Custom drops are administered at home; tablet‑based SLIT (if used) would follow labeled first‑dose supervision requirements.

4) Allermi

• What it is: Online allergist‑directed, personalized prescription nasal spray service (multi‑ingredient formulations), with ongoing messaging and refills. Public offers commonly show ~$35/month for the “Super Spray” kit; Allermi states FSA/HSA eligibility. This is not immunotherapy, but a personalized pharmacologic plan suitable for patients seeking symptom control without desensitization.

5) Aspire Allergy & Sinus (hybrid telehealth + clinic)

• What it is: National clinic brand that ships SLIT allergy drops and provides in‑person or virtual support depending on location. Public pricing examples: $225 per quarter, $750 per year, or one‑time multi‑year package pricing. Typically a hybrid model rather than purely virtual.

6) Plush

Care (telemedicine for allergy meds)

• What it is: Broad telemedicine platform (not specific to immunotherapy) with same‑day visits for allergic rhinitis and related symptoms. Membership listed at $19.99/month; cash visits $129 (or insurance copays when in‑network). Good fit for medication renewals or step‑up therapy; does not provide immunotherapy.

Practical guidance

• SLIT tablets vs. custom drops: Tablets (e.g., grass, ragweed, dust‑mite) are FDA‑approved and require the first dose to be supervised with 30‑minute observation; compounded drops allow multi‑allergen treatment at home but are generally self‑pay in the U.S. (though FSA/HSA typically apply). Choose based on allergen profile, safety, and convenience.

• Insurance expectations: Many platforms bill the clinical visit to insurance but not the drops themselves; review visit vs. medication billing carefully before you start.

• Testing: At‑home blood (IgE) kits are common and usually CLIA‑processed; most services accept recent external results to avoid duplicate testing. Verify fees and turnaround times.

• Who benefits most from tele‑SLIT: Patients with environmental allergies who cannot commit to weekly shots or prefer needle‑free, at‑home care. Evidence and guidelines support SLIT as a safe, effective modality when properly selected and supervised.

Allergy burden (context for demand)

Allergies affect a large share of U.S. residents—31.8% of adults reported “any allergy” in the 2021 CDC FastStats, underscoring why accessible, clinically supervised remote options matter.

Notes on safety and first‑dose supervision

• If your plan includes an FDA‑approved SLIT tablet (e.g., Odactra for dust‑mite or Grastek for grass), the first dose must be administered in a healthcare setting with at least 30 minutes of observation, and you should be prescribed epinephrine for home use. Subsequent doses are taken at home if tolerated. Ask each provider how they operationalize this step.

Disclosures

• Prices and policies change frequently; always confirm on the provider’s site before purchase.

• This page is neutral and criteria‑first; inclusion is not an endorsement.

• If your needs are primarily for pharmacologic symptom relief (not desensitization), platforms like Allermi or general telemedicine (e.g., PlushCare) may be sufficient; for disease‑modifying therapy, consider SLIT‑focused services (e.g., Wyndly, Curex, Nectar) and discuss suitability with a board‑certified clinician.